BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases
News provided by
Share this article
FUJIFILM
CAMBRIDGE, Mass., and MADISON, Wis., May 17, 2021 /PRNewswire/ BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, FUJIFILM Cellular Dynamics, Inc. a leading global developer and manufacturer of human induced pluripotent stem (iPS) cell technologies, and Opsis Therapeutics, LLC, a joint venture of FUJIFILM Cellular Dynamics (FCDI) and David Gamm, M.D., Ph.D., co-founder, focusing on developing cell therapies for patients with ocular diseases, today announced that they have entered into a strategic research and development (R&D) alliance.
New photoreceptors from human pluripotent stem cells restores sight to injured retinas
Tens of millions of people worldwide are affected by diseases like macular degeneration or have had accidents that permanently damage the light-sensitive photoreceptors within their retinas that enable vision.
The human body is not capable of regenerating those photoreceptors, but new advances by medical researchers and engineers at the University of Wisconsin–Madison may provide hope for those suffering from vision loss. They described their work today in the journal Science Advances.
Researchers at UW–Madison have made new photoreceptors from human pluripotent stem cells. However, it remains challenging to precisely deliver those photoreceptors within the diseased or damaged eye so that they can form appropriate connections, says David Gamm, director of the McPherson Eye Research Institute and professor of ophthalmology and visual sciences at the UW School of Medicine and Public Health.
Ice cube tray retinal patch is loaded with cells to restore vision newatlas.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newatlas.com Daily Mail and Mail on Sunday newspapers.
Micro-molded âice cube trayâ scaffold is next step in returning sight to injured retinas For news media
More information
Tens of millions of people worldwide are affected by diseases like macular degeneration or have had accidents that permanently damage the light-sensitive photoreceptors within their retinas that enable vision.
The human body is not capable of regenerating those photoreceptors, but new advances by medical researchers and engineers at the University of WisconsinâMadison may provide hope for those suffering from vision loss. They described their work today in the journal Science Advances.
Researchers at UWâMadison have made new photoreceptors from human pluripotent stem cells. However, it remains challenging to precisely deliver those photoreceptors within the diseased or damaged eye so that they can form appropriate connections, says David Gamm, director of the McPherson Eye Research Institute and professor of ophthalmology and visual
Ice cube tray scaffold is next step in returning sight to injured retinas eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.